undamentalytics Newsletter

Burke Steven Keith: insider trades

Officer at 2 companies we cover. 2 open-market purchases and 7 sales not made under a pre-set plan, reported from December 18, 2017 to May 9, 2024.

Would copying Burke Steven Keith’s purchases have beaten the S&P 500?

Too few purchases to judge. None of their purchases has 12 months of prices after the report; we judge insiders once they have 20. The figures below can swing a long way on a handful of trades. None of their purchases could be priced, so there is no copy portfolio. None of these trades can be measured yet: either the window after the report has not finished or the share price was under $5 when it was reported.

With 296 insiders tested, some will look skilled or unskilled by chance alone: when we replaced each insider’s stocks with random companies bought on the same days, about 5.7 cleared the bar ahead and 23.3 behind. One record on its own proves little.

Trade by trade

Burke Steven Keith: trades against the S&P 500 afterwards
MeasuredTrades countedAverage vs S&P 500MedianWent the right wayYearst-statisticp-valueEvidence
Purchases, 3 months after the report 0 — — — — — — Not enough years
Purchases, 6 months after the report 0 — — — — — — Not enough years
Purchases, 12 months after the report 0 — — — — — — Not enough years
Purchases, 12 months after the trade 0 — — — — — — Not enough years
Sales, 3 months after the report 0 — — — — — — Not enough years
Sales, 12 months after the report 0 — — — — — — Not enough years
Sales, 12 months after the trade 0 — — — — — — Not enough years

“Average vs S&P 500” is the stock’s return including dividends minus the index’s over the same dates, from the close on the first trading day after the report, or from the close on the trade date. Only windows that have finished are counted. For sales, a negative figure means the stock lagged after it was sold, so selling was the right call (green). “Went the right way” is the share of purchases that beat the index, or of sales that trailed it. The t-statistic uses one average per year of reports, because one person’s trades bunch into the same stock and weeks, and needs trades in at least four different years; the p-value comes from the t distribution with that number of years (with four years, a t of 2 has p = 0.14). “Some evidence” means p under 5%, “strong evidence” p under 1% over at least six years.

Companies traded

CompanyTitle on the latest filingPurchasesSalesFirst reportLatest report
Akebia Therapeutics, Inc. AKBA SVP, Chief Medical Officer17November 22, 2019May 9, 2024
Protara Therapeutics, Inc. TARA SVP and Chief Medical Officer10December 18, 2017December 18, 2017

Trades and what followed

Moves are against the S&P 500; green means the trade went the insider’s way.

ReportedTradedCompanyTradeValue3 months after report12 months after report12 months after trade
May 9, 2024August 25, 2023 AKBA Sale $31,050 not yetnot yetnot yet
March 1, 2024February 29, 2024 AKBA Sale $11,327 not yetnot yetnot yet
February 2, 2024February 1, 2024 AKBA Sale $40,842 not yetnot yetnot yet
May 18, 2023May 16, 2023 AKBA Sale $68,017 not yetnot yetnot yet
March 3, 2023March 1, 2023 AKBA Sale $12,428 not yetnot yetnot yet
March 2, 2022February 28, 2022 AKBA Sale $32,524 not yetnot yetnot yet
March 2, 2021March 1, 2021 AKBA Sale $25,697 not yetnot yetnot yet
November 22, 2019November 20, 2019 AKBA Purchase $96,660 not yetnot yetnot yet
December 18, 2017December 15, 2017 TARA Purchase $22,560 not yetnot yetnot yet

Open-market purchases and sales of at least $10,000 in companies we cover, from SEC Form 4 filings; sales made under a pre-set Rule 10b5-1 plan are not shown. “Not yet” means the window has not finished or the share price was under $5 at entry. These are the shares’ moves after each trade: they say nothing about why Burke Steven Keith traded and do not suggest the use of non-public information. How every insider compares · the insider trading backtest.